Author

Sophie Papa

Guy's HospitalORCID 0000-0002-9063-7675Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

Anna SchurichiD· 1 shared Daniel Larcombe-YoungiD· 1 shared Ellen King· 1 shared Esperanza PeruchaiD· 1 shared Eva Bugallo-BlancoiD· 1 shared Katie R FlahertyiD· 1 shared Khadiza Siddika· 1 shared Molly S. Cook· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

Anna SchurichORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A balanced CAR-T cell metabolism driven by CD28 or 4-1BB co-stimulation correlates with clinical success in lymphoma patients

Molly S. Cook, Ellen King, Katie R Flaherty, Khadiza Siddika, Sophie Papa, Reuben Benjamin, Anna Schurich

Ex vivo profiling of patient CD19 CAR-T cells shows CD28 products skew glycolytic and effector-like while 4-1BB products favor OXPHOS; complete responders show balanced metabolism.

Cell Reports · Jul 1, 2025Peer-reviewedImmunology✦ In-depth digest

GLUT5 armouring enhances adoptive T cell therapy anti-tumour activity under glucose-limiting conditions

Robert Lee Page II, Olivier Martínez, Daniel Larcombe-Young, Eva Bugallo-Blanco, Sophie Papa, Esperanza Perucha

This paper shows that modifying T cells to use fructose via GLUT5 improves their anti-tumor activity in low-glucose environments.

Immunotherapy Advances · Dec 30, 2024Peer-reviewedCancer Biology